Navigation Links
MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
Date:11/9/2010

WARREN, N.J., Nov. 9, 2010 /PRNewswire/ -- MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,824,588 from the United States Patent and Trademark Office (USPTO). The patent, issued on November 2, 2010, provides intellectual property protection for the Company's film products and methods of their preparation.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "Our patented PharmFilm® and production technologies are very important to ensuring that drug containing films are manufacturable, content uniform, stable and deliver the in-vivo performance that is expected from each and every dose.  Importantly, this patent also signals to the entire pharmaceutical industry that PharmFilm® is an ideal vehicle for delivering a variety of dosage strengths and sensitive prescription drug targets, including peptides and proteins as well as small molecules."

Mr. Schobel continued, "Our patent estate continues to strategically grow thereby affording us and our partners a strong and protected product position within the market."

Keith Kendall, executive vice president and CFO of MonoSol Rx said, "We are a technology company, a partnering company and an innovator.  Our strategy is to apply our technology, alone or in combination with others, to add value to our current and prospective partners.  Continuing to innovate and thereby expand the value and applicability of our PharmFilm® platform is critical to the success of MonoSol Rx.  As such, we invest significant time and resources to broaden and protect our intellectual property, and we believe this latest patent gives us, and by extension our partners, significant competitive advantage."

About MonoSol RxMonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone®  sublingual film, the first combination sublingual film product for the treatment of opioid dependence.  

MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing.  For existing and future partners, PharmFilm® formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).  For press releases and other company information visit www.monosolrx.com Contacts:MonoSol Rx:Keith KendallChief Financial Officer(732) 564-5000The Ruth Group (on behalf of MonoSol Rx)Jason Rando (media)(646) 536-7025jrando@theruthgroup.com  Sara Pellegrino (investors)(646) 536-7002spellegrino@theruthgroup.com  
'/>"/>

SOURCE MonoSol Rx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
2. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
3. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
4. Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC
5. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
6. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
7. Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
8. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
9. Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent
10. Sixth U.S. Patent Issued to Dyadic International
11. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Solentim, the developer of instrumentation for ... a major new product line called the VIPS™ ... has been developed for automatically seeding single cells ... of the process to generate clonally-derived cell lines. ... reliable solution when compared to traditional single cell ...
(Date:4/20/2017)... April 20, 2017  Vivify Health, the pioneer and ... been awarded a very significant patent for the advancement ... continual care via digital health.  This landmark patent provides ... and further secures Vivify,s position as the leader in ... was the first company to apply consumer mobile devices, ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... from the Company,s consumer product development program, based ... the Society for Investigative Dermatology (SID) 76 th ... advance and promote the sciences relevant to skin ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in South Florida ... report in the May issue of Consumer Reports focused on heart health. , ... achieved during and after coronary bypass and aortic valve replacement procedures. , Consumer ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... the continuation of its strategic partnership with and platinum sponsorship of Global Spine ... the safe and effective management of complex spine deformity cases, particularly in children. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS ... Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. ... pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit for ...
(Date:4/24/2017)... DC (PRWEB) , ... April 24, 2017 , ... The ... recognized during ATA 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, on ... Santana Telehealth Project for using telemedicine to improve the lives of the poor and ...
(Date:4/24/2017)... ... ... As part of the nationwide Days of Remembrance effort led by the United ... persecution, Center for Medicine after the Holocaust (CMATH) announced that it will ... and Poland next week. , The Fourth Biennial CMATH Champions Trip to Germany and ...
Breaking Medicine News(10 mins):